May 15, 2025

Higher Medicine Joins BIO 2025 in Boston as a part of the Maryland Delegation

Higher Medicine is excited to attend the 2025 BIO International Convention from June 16–19 in Boston, MA, as a part of the official Maryland Department of Commerce delegation, and is participating in the Partnering Forum. BIO is the world’s largest and most influential biotech gathering, bringing together thousands of leaders in science, business, and investment.

We’ll be sharing our approach to developing targeted small molecule therapies for rare pediatric diseases like Kabuki Syndrome and Friedreich’s Ataxia, with long-term expansion into conditions such as Alzheimer’s and aging-related disorders.

Our pipeline is built on validated mechanisms, strong safety data, and a clear regulatory path to Phase 2a trials. We welcome conversations with investors, strategic partners, and scientific collaborators who share our vision for purpose-driven innovation in medicine.

Let’s connect in Boston to explore how we can work together to bring breakthrough therapies to patients faster.

🔗 Learn more about BIO 2025: https://www.bio.org/events/bio-international-convention

Latest News

Our platform offers a variety of resources to keep you informed about our latest programs, key updates, achievements, and other significant developments in the field of healthcare and medicine.

Company Announcements
June 16, 2025

Higher Medicine Announces a Pre-Seed Builder Fund Investment from TEDCO

TEDCO's Pre-Seed Builder Fund, one of the state's marquee investment vehicles in Maryland, invested in Higher Medicine.

Read more
Company Announcements
June 12, 2025

Higher Medicine Announces Strategic Investment and Clinical Alliance with 5 Horizons Capital to Advance a Clinical Trial

Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.

Read more
Company Announcements
June 2, 2025

Higher Medicine Announces Exclusive Option Agreement with Johns Hopkins Technology Ventures for Epigenetic Drug Candidate Screening Technology

Higher Medicine has entered into an exclusive option agreement with Johns Hopkins Technology Ventures (JHTV) to advance development of a proprietary histone reporter allele platform for epigenetic drug discovery.

Read more
Company Announcements
April 25, 2025

Higher Medicine Selected for the Maryland TEDCO SBIR/STTR Proposal Lab 2025 Cohort

Funded by TEDCO and administered by the leading experts in the field, Proposal Lab supports companies in securing competitive and prestigious NSF and other grants to advance their R&D portfolios.

Read more
Company Announcements
April 25, 2025

Higher Medicine Selected for HiveBio Accelerator Cohort

HiveBio Accelerator program offers world-class training, mentorship, and support to help scale Higher Medicine and secure follow-on funding.

Read more
Company Announcements
April 25, 2025

Higher Medicine Secures $500,000 Seed Investment from Desire Ventures

Higher Medicine seed investment secured from Desire Ventures

Read more